A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

December 4, 2018

Study Completion Date

December 11, 2018

Conditions

Atopic Dermatitis

Interventions

DRUG

Bermekimab Monoclonal Antibody 200 mg

200 mg subcutaneous injection

DRUG

Bermekimab Monoclonal Antibody 400 mg

400 mg subcutaneous injection

Trial Locations (1)

Florida Academic Centers Research & Education, Coral Gables

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03496974 - A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter